Related Experiment Video

Updated: Jun 24, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-alpha

Masanori Ikeda1, Kyoko Mori, Yasuo Ariumi

  • 1Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. maikeda@md.okayama-u.ac.jp

FEBS Letters
|April 1, 2009
PubMed

Insights

Oncostatin M (OSM) shows significant anti-hepatitis C virus (HCV) activity. It also enhances interferon-alpha therapy, offering a potential new treatment for chronic hepatitis C patients.

Area of Science:

  • Immunology
  • Virology
  • Hepatology

Background:

  • Oncostatin M (OSM), an interleukin-6 family cytokine, has known roles in hepatocyte differentiation and melanoma growth suppression.
  • Hepatitis C virus (HCV) infection remains a significant global health concern, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the potential anti-HCV activity of Oncostatin M (OSM).
  • To evaluate the synergistic effects of OSM with interferon-alpha (IFN-alpha) in combating HCV infection.

Main Methods:

  • Utilized an HCV RNA replication cell culture system to assess OSM's antiviral efficacy.
  • Determined the 50% effective concentration (EC50) of OSM against HCV replication.
  • Investigated the combined effect of OSM and IFN-alpha on HCV replication at various concentrations.

Main Results:

  • OSM demonstrated potent anti-HCV activity with an EC50 of 0.71 ng/ml.
  • OSM exhibited significant synergistic inhibitory effects with IFN-alpha, even at low concentrations (25 pg/ml).
  • The combination therapy showed enhanced suppression of HCV replication compared to either agent alone.

Conclusions:

  • Oncostatin M possesses a novel anti-HCV activity.
  • OSM is a promising candidate reagent for anti-HCV therapy.
  • OSM may improve the efficacy of current interferon-based treatments for chronic hepatitis C.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...